Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2016

01-10-2016 | Original Article

Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study

Authors: Hiang Keat Tan, Paul Damien James, Florence Wong

Published in: Digestive Diseases and Sciences | Issue 10/2016

Login to get access

Abstract

Background

Large-volume total paracentesis may result in paracentesis-induced circulatory dysfunction, which is associated with poor outcomes.

Aims

To explore the short- and long-term effects of paracentesis-induced circulatory dysfunction on systemic hemodynamics, renal function and other cirrhosis-related complications in patients with refractory ascites, following subtotal large-volume paracentesis.

Methods

Patients with cirrhosis and refractory ascites without renal dysfunction had systemic hemodynamics, renal function, and neurohormones (plasma active renin, aldosterone, norepinephrine and angiotensin II) measured pre- and 6 days post-paracentesis. Paracentesis was limited to ≤8 L with 6–8 g of albumin per liter ascites drained. Patients were followed up until transjugular intrahepatic portosystemic shunt insertion, liver transplantation, or death. Paracentesis-induced circulatory dysfunction was defined as >50 % increase in plasma active renin 6 days post-paracentesis.

Results

Fifty-seven patients (mean age 59.0 ± 9.4 years) had mean 6.8 ± 1.8 L of ascites removed with 9 ± 3 g of albumin given/L of ascites drained. Patients were followed up for 715 ± 104 days. Twenty-three patients (40.4 %) developed paracentesis-induced circulatory dysfunction with unchanged serum creatinine on day six, despite worsening of hemodynamics (mean arterial pressure 90 ± 10 mmHg at baseline vs. 84 ± 8 mmHg on day six, p < 0.05). Similar hemodynamic changes were observed among patients without paracentesis-induced circulatory dysfunction. There was no significant difference in the long-term renal function or cirrhosis-related complications between the groups.

Conclusion

The occurrence of paracentesis-induced circulatory dysfunction, as defined by plasma active renin, may not have a significant short- and long-term impact on renal function or cirrhosis-related complications in patients with refractory ascites who undergo subtotal paracentesis with albumin infusion.
Literature
1.
go back to reference D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–231.CrossRefPubMed D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–231.CrossRefPubMed
2.
go back to reference Bellot P, García-Pagán JC, Francés R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010;52:2044–2052.CrossRefPubMed Bellot P, García-Pagán JC, Francés R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology. 2010;52:2044–2052.CrossRefPubMed
3.
go back to reference Cardenas A, Arroyo V. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab. 2003;17:607–622.CrossRefPubMed Cardenas A, Arroyo V. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab. 2003;17:607–622.CrossRefPubMed
4.
go back to reference Schrier RW, Shchekochikhin D, Ginès P. Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis. Nephrol Dial Transplant. 2012;27:2625–2628.CrossRefPubMed Schrier RW, Shchekochikhin D, Ginès P. Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis. Nephrol Dial Transplant. 2012;27:2625–2628.CrossRefPubMed
5.
go back to reference Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087–2107.CrossRefPubMed Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087–2107.CrossRefPubMed
6.
go back to reference European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.CrossRef
7.
go back to reference Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology. 1997;113:579–586.CrossRefPubMed Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology. 1997;113:579–586.CrossRefPubMed
8.
go back to reference Vila MC, Solà R, Molina L, et al. Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. J Hepatol. 1998;28:639–645.CrossRefPubMed Vila MC, Solà R, Molina L, et al. Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. J Hepatol. 1998;28:639–645.CrossRefPubMed
9.
go back to reference Ginès P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94:1493–1502.CrossRefPubMed Ginès P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94:1493–1502.CrossRefPubMed
10.
go back to reference Nasr G, Hassan A, Ahmed S, Serwah A. Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites. J Cardiovasc Dis Res. 2010;1:136–144.CrossRefPubMedPubMedCentral Nasr G, Hassan A, Ahmed S, Serwah A. Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites. J Cardiovasc Dis Res. 2010;1:136–144.CrossRefPubMedPubMedCentral
11.
go back to reference Ginès A, Fernández-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996;111:1002–1010.CrossRefPubMed Ginès A, Fernández-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996;111:1002–1010.CrossRefPubMed
12.
go back to reference Appenrodt B, Wolf A, Grünhage F, et al. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int. 2008;28:1019–1025.CrossRefPubMed Appenrodt B, Wolf A, Grünhage F, et al. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int. 2008;28:1019–1025.CrossRefPubMed
13.
go back to reference Sola-Vera J, Miñana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology. 2003;37:1147–1153.CrossRefPubMed Sola-Vera J, Miñana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology. 2003;37:1147–1153.CrossRefPubMed
14.
go back to reference Singh V, Kumar R, Nain CK, Singh B, Sharm AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol. 2006;21:303–307.CrossRefPubMed Singh V, Kumar R, Nain CK, Singh B, Sharm AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol. 2006;21:303–307.CrossRefPubMed
15.
go back to reference Singh V, Dheerendra PC, Singh B, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol. 2008;103:1399–1405.CrossRefPubMed Singh V, Dheerendra PC, Singh B, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol. 2008;103:1399–1405.CrossRefPubMed
16.
go back to reference Singh V, Kumar B, Nain CK, et al. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med. 2006;260:62–68.CrossRefPubMed Singh V, Kumar B, Nain CK, et al. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med. 2006;260:62–68.CrossRefPubMed
17.
go back to reference Sola-Vera J, Miñana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology. 2003;37:1147–1153.CrossRefPubMed Sola-Vera J, Miñana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology. 2003;37:1147–1153.CrossRefPubMed
18.
go back to reference Peltekian KM, Wong F, Liu PP, Logan AG, Sherman M, Blendis LM. Cardiovascular, renal and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. Am J Gastroenterol. 1997;92:394–399.PubMed Peltekian KM, Wong F, Liu PP, Logan AG, Sherman M, Blendis LM. Cardiovascular, renal and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites. Am J Gastroenterol. 1997;92:394–399.PubMed
19.
go back to reference Salerno F, Guevara M, Bernardi M, et al. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 2010;30:937–947.CrossRefPubMed Salerno F, Guevara M, Bernardi M, et al. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 2010;30:937–947.CrossRefPubMed
20.
go back to reference Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Ascites Club. J Hepatol. 2015;62:968–974.CrossRefPubMed Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Ascites Club. J Hepatol. 2015;62:968–974.CrossRefPubMed
21.
go back to reference Eriksson BM. Determination of catecholamines in rat heart tissue and plasma samples by liquid chromatography with electrochemical detection, by B.-M. Eriksson and B.-A. Persson. J Chromatogr. 1993;612:1–5.CrossRefPubMed Eriksson BM. Determination of catecholamines in rat heart tissue and plasma samples by liquid chromatography with electrochemical detection, by B.-M. Eriksson and B.-A. Persson. J Chromatogr. 1993;612:1–5.CrossRefPubMed
23.
go back to reference Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55:1172–1181.CrossRefPubMed Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55:1172–1181.CrossRefPubMed
24.
go back to reference Pozzi M, Osculati G, Boari G, et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology. 1994;106:709–719.CrossRefPubMed Pozzi M, Osculati G, Boari G, et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology. 1994;106:709–719.CrossRefPubMed
25.
go back to reference Planas R, Ginès P, Arroyo V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology. 1990;99:1736–1744.CrossRefPubMed Planas R, Ginès P, Arroyo V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology. 1990;99:1736–1744.CrossRefPubMed
26.
go back to reference de Bruin RA, Bouhuizen A, Diederich S, Perschel FH, Boomsma F, Deinum J. Validation of a new automated renin assay. Clin Chem. 2004;50:2111–2116.CrossRefPubMed de Bruin RA, Bouhuizen A, Diederich S, Perschel FH, Boomsma F, Deinum J. Validation of a new automated renin assay. Clin Chem. 2004;50:2111–2116.CrossRefPubMed
27.
go back to reference Unger N, Lopez Schmidt I, Pitt C, et al. Comparison of active renin concentration and plasma adrenal activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass. Eur J Endocrinol. 2004;150:517–523.CrossRefPubMed Unger N, Lopez Schmidt I, Pitt C, et al. Comparison of active renin concentration and plasma adrenal activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass. Eur J Endocrinol. 2004;150:517–523.CrossRefPubMed
28.
go back to reference Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary hyperaldosteronism. J Hypertension. 2004;22:377–381.CrossRef Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary hyperaldosteronism. J Hypertension. 2004;22:377–381.CrossRef
29.
go back to reference Corbin F, Douville P, Lebel M. Active renin mass concentration to determine aldosterone-to-renin ratio in screening for primary aldosteronism. Int J Nephrol Renovasc Dis. 2011;4:115–120.PubMedPubMedCentral Corbin F, Douville P, Lebel M. Active renin mass concentration to determine aldosterone-to-renin ratio in screening for primary aldosteronism. Int J Nephrol Renovasc Dis. 2011;4:115–120.PubMedPubMedCentral
30.
go back to reference Sersté T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011;55:794–797.CrossRefPubMed Sersté T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011;55:794–797.CrossRefPubMed
31.
go back to reference Wong F. Drug insight: the role of albumin in the management of chronic liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007;4:43–51.CrossRefPubMed Wong F. Drug insight: the role of albumin in the management of chronic liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007;4:43–51.CrossRefPubMed
32.
go back to reference Coll S, Vila MC, Molina L, Gimenez MD, Guarner C, Solá R. Mechanisms of early decrease in systemic vascular resistance after total paracentesis: influence of flow rate of ascites extraction. Eur J Gastroenterol Hepatol. 2004;16:347–353.CrossRefPubMed Coll S, Vila MC, Molina L, Gimenez MD, Guarner C, Solá R. Mechanisms of early decrease in systemic vascular resistance after total paracentesis: influence of flow rate of ascites extraction. Eur J Gastroenterol Hepatol. 2004;16:347–353.CrossRefPubMed
33.
go back to reference Sola-Vera J, Such J. Understanding the mechanisms of paracentesis-induced circulatory dysfunction. Eur J Gastroenterol Hepatol. 2004;16:295–298.CrossRefPubMed Sola-Vera J, Such J. Understanding the mechanisms of paracentesis-induced circulatory dysfunction. Eur J Gastroenterol Hepatol. 2004;16:295–298.CrossRefPubMed
34.
go back to reference Sarma MS, Yachha SK, Bhatia V, Srivastava A, Poddar U. Safety, complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease. J Hepatol. 2015;63:1126–1132.CrossRefPubMed Sarma MS, Yachha SK, Bhatia V, Srivastava A, Poddar U. Safety, complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease. J Hepatol. 2015;63:1126–1132.CrossRefPubMed
35.
go back to reference Boyer JK, Thanigaraj S, Schechtman KB, Pérez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol. 2004;93:870–875.CrossRefPubMed Boyer JK, Thanigaraj S, Schechtman KB, Pérez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol. 2004;93:870–875.CrossRefPubMed
36.
go back to reference Patil VC, Patil HV, Shah KB, Vasani JD, Shetty P. Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function. J Cardiovasc Dis Res. 2011;2:213–222.CrossRefPubMedPubMedCentral Patil VC, Patil HV, Shah KB, Vasani JD, Shetty P. Diastolic dysfunction in asymptomatic type 2 diabetes mellitus with normal systolic function. J Cardiovasc Dis Res. 2011;2:213–222.CrossRefPubMedPubMedCentral
Metadata
Title
Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study
Authors
Hiang Keat Tan
Paul Damien James
Florence Wong
Publication date
01-10-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4140-3

Other articles of this Issue 10/2016

Digestive Diseases and Sciences 10/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine